CORAT (Corona Antibody Team)

・ Please understand that the TU Braunschweig, this department or it's Employees are not able to provide access to medications or clinical studies, nor provide medical advice.

Development of SARS-CoV-2 neutralising antibodies against COVID19


COR-101 ready for clinical trials
Photo credit: Prof. Holger Ziehr/Fraunhofer ITEM
Fraunhofer ITEM staff present the final vial of the fill and finish of the first larger GMP manufacturing run using an innovative cell pool technology.

18.11.2020 - CORAT lead product COR-101 ready for clinical trials

CORAT Therapeutics CEO Dr. Andreas Herrmann today reports the conclusion of the production campaign providing the first larger batch of COR-101 ready for the patients: „We are extremely happy and would like to thank everybody who helped to make this happen so quickly. With acute case numbers rising fast, CORAT hopes to make a difference by providing an option soon to directly treat the Coronavirus-Infected. We hope that the clinical studies now can commence very soon.“    

Innovationsprteis für CORAT
Photo credit: Innovationsnetzwerk Niedersachsen/Fotograf: Henning Scheffen
Innovation Avard of the State of Lower Saxony for CORAT : Björn Thümler, Minister of Science; Prof. Michael Hust, TU Braunschweig; Dr. Bernd Althusmann, Minister for Economy, Dr. Thomas Schirrmann, CEO of Yumab GmbH, Prof. Josef von Helden, Director of the Board of Innovation Nework Niedersachsen (from the left).

16.7.2020 - Fraunhofer ITEM and Corat Therapeutics GmbH start accelerated production of a passive vaccine against COVID-19.

16.6.2020 - With support from the German Federal State of Lower Saxony, CORAT Therpeutics was formed as a dedicated body to promote the further development of the antibody based COVID-10 medicine.

press release

5.6.2020 - CORAT publishes the first substantial dataset describing fully human antibodies from heathly donors that are able to block the infection by SARS-CoV-2.


[Translate to English:] CORAT antibodies blocking SARS-CoV-2 infection
Photo credit: CORAT/TU Braunschweig
[Translate to English:] CORAT antibodies blocking SARS-CoV-2 infection (docking model: Luca Varani)
Photo credit: CORAT/ CORAT Therapeutics GmbH

CORAT Therapeutics GmbH now coordinates the clinical development

4.5.2020 - CORAT member YUMAB, spinoff of the Department of Biotechnology of the TU Braunschweig, generated a neutralising coronavirus antibody protecting against SARS-CoV-2 infection, as confirmed by the Helmholtz Center for Infection Reserach

CORAT member YUMAB generated protective coronavirus antibody
Photo credit: Schirrmann/Frenzel /Yumab GmbH
Dr. Thomas Schirrmann and Dr. André Frenzel of CORAT member YUMAB

Fighting COVID19 with recombinant fully human Antibodies neutralizing SARS-CoV2

CORAT is a consortium of academic and industrial partners with the mutual goal to develop a passive vaccination immunotherapy against COVID-19 employing novel fully human monoclonal antibodies neutralizing SARS-CoV2.

Coordination: Prof. Dr. Stefan Dübel, Prof. Dr. Michael Hust (TU Braunschweig).

Coordination CORAT Therapeutics GmbH: Dr. Andreas Herrmann

What we do.

A large set of more than 750 human monoclonal antibodies recognizing SARS-CoV2 Spike (S) protein isolated by antibody phage display from human antibody libraries from healthy donors and convalescent COVID-19 patients underwent a fast track development process to identify lead molecule with optimal drug features for a passive vaccine. The best antibody currently is in production to be clinically tested soon as immunotherapy to treat acute COVID-19. Moreover, this drug candidate may also be applied in a prophylactic scheme to protect medical care personnel or impaired patients. Innovative and state of the art methods are used to manufacture the drug candidate in much shorter time than ever done so far while keeping all necessary safety and quality requirements for medical use substances.

CORAT Neutralisating Antibody development
Photo credit: Thomas Schirrmann/Yumab GmbH

How CORAT antibodies protect against severe COVID19

Recombinant human virus-neutralizing antibodies are the active component of the immunotherapy (also passive vaccine). Antibodies (immunogobulins, IgG) are molecules made by our own body to protect us against infections.

The CORAT antibody neutralize SARS-CoV2 after injection and immediately provides the protection in exactly the same way like antibodies would do from our own body once they are generated by the infection or by vaccination. The CORAT antibody stops the virus and protects the patients until their immunity generates their own antibodies. This drug should be very well tolerated, because it is identical to human antibodies (“fully human”) - actually, its exact sequences were taken out of a healthy donor.

Due to the long serum half time, the CORAT antibody could be given in an early and acute stage of SARS-CoV2 infection with immediate antiviral effect and long protection until the body has the time to produce enough of its own IgG.

How are CORAT antibodies different from a typical vaccine?

A typical vaccine ("active vaccine”) consisting of dead or partial virus material cannot heal COVID19 patients.  The reason is that active vaccines induce an immune response - typically the generation of antibodies (IgG) - like the infection does itself. However, the development of protecting antibodies takes up to 2-3 weeks, too long for patients with a severe infection to survive. Therefore, patients that are already infected do not benefit from such an active vaccine. The same is true for medical care personnel in emergency situations, because immunological protection starts only several weeks after the vaccination.

In contrast, CORAT antibody immunotherapy (also named "passive vaccine") supplements the not yet existing antibodies in the patient's body from the very time of injection, thus helping to lower the virus burden immediately. An active vaccine can protect healthy persons after some weeks, but it does not help patients already infected. Further, it cannot provide immediate protection to risk groups and exposed medical care personnel. CORAT antibodies can fill this treatment gap and thus perfectly complement virus-based vaccines.

As it will take many years to completely vaccinate the world's entire population, acute severe cases will be seen in our clinics for a long time to come, and a medication to help these patients is urgently needed.


Serum therapy is established since 120 years and well tolerated

  • Serum therapy uses (un-defined) mixtures of antibodies from immunized animals or convalescent patients to neutralize pathogens
  • Introduced by Emil v. Behring in the late 19th century (First Nobel prize for medicine 1901), countless children cured (diphtheria)
  • although effective, side effects of animal serum therapy were seen (which are completely avoided by fully human CORAT design)
  • IVIG (pooled human IgG from plasma donors) is still broadly used
  • Recent results demonstrate the efficacy of neutralising antibodies against SARS-CoV-2, with a 72% reduction in hospitalisation (development of more severe symthomas) in the BLAZE-1 study by Lilly (NCT04427501).

Recombinant neutralising antibodies are a proven class of drugs

There is already an approved antibody neutralizing drug against lung viruses, which eliminates the disadvantages of serum therapy, and shows how well antibodies can be tolerated.

  • Synagis® (palivizumab): Prevention of respiratory syncytial virus (RSV) infection, approved to be used as a precautionary measure in premature babies, infants and toddlers with previous illnesses (prophylactic administration).

Technology behind CORAT

  • CORAT antibodies are made by Nobel-prize awarded molecular biology technique "antibody phage display" to isolate human monoclonal antibodies from blood that are indistinguishable from our own bodies antibodies - with one difference: they prevent SARS-CoV-2 infection
  • To minimize potential side effects, every biomolecule in a CORAT medication is made from a gene directy obtained from human donors, i.e. it has already been produced before in a healthy person - there are no synthetic parts, no chemical modifications etc. involved.
  • CORAT member TU Braunschweig has already successfully generated neutralising antibodies to other deadly viruses, for example our antibody X10H2 against SudanEbola Virus (protective in in vivo tests , PNAS. 2020 117:3768-3778 ), VEEV, WEEV, Marburg Virus, and many pathogenic Toxins.
  • Some of these antibodies, e.g. our antibodies against diphtheria toxins, performed better in inhibition than the currently used serum-derived clinical standard treatment, as confirmed by the NIBSC, see (Sci Rep. 2020, 10:571)
  • CORAT member YUMAB already has developed numerous fully human antibodies for leading pharmaceutical companies, and made the first anti-COVID-19 drug candidate YU505-E01.

CORAT antibody prevents infection with SARSCoV2 isolated from COVID19 patient

Photo credit: HZI/Yumab/TU Braunschweig

Infection of cells (in cell culture) with SARS-CoV2 isolates from a COVID19 patient lead to their lysis, indicated by rounding and loss of confluence (upper left panel). Uninfected cells (upper right) grow normally (no dead round dots). Lower right: Adding the CORAT antibody from Yumab to infected cells completely protected the cells from infection for 5 days, while a negative control antibody (lower left panel) did not protect the cells (Fotos: light microscopy)

(Data: HZI, Prof. Čičin-Šain)

download more information here

Who we are: the team

Originally initiated by Prof. Stefan Dübel, YUMAB founder and head of the Biotechnology Department of the University of Braunschweig and his colleague Prof. Michael Hust, together with  Prof. Gundram Jung of University of Tübingen, CORAT expanded to a consortium of more than 30 scientists and clinicians from academic institutions and industry. CORAT members represent competence from infection research, antibody development and manufacturing to bedside and have joined forces to supply acute COVID19 patients with a well-tolerated treatment to eliminate SARS-CoV2.

Prof. Michael Hust (TU Braunschweig) is part of the EU Horizon2020 COVID19 consortium "ATAC". We are also grateful for rapid emergency funding from the Land Niedersachsen, and funding by the Deutsche Herzstiftung e.V., Frankfurt a.M.

Since 16.6.2020, the preclinical and clinical development is coordinated by CORAT Therapeutics GmbH, a company founded for that purpose with support by the State of Lower Saxony.

Antibodies for COVID-19 research und diagnostics

Abcalis antibodies binding to SARS-CoV-2 N-Protein

...finally, please feel free to visit Abcalis, another award winning spin off of TU Braunschweig, providing animal free antibodies against the SARS-CoV2 spike and N proteins (already 100% compliant to the new recommendations of EU (EURL ECVAM JRC120199) / EU Directive 2010/63/EU).

Abcalis' anti-SARS-CoV-2 antibodies are currently in development for rapid antigen detection tests with partner companies.


Prof. Dr. Stefan Dübel / Prof. Dr. Michael Hust
Technische Universität Braunschweig, Institute of Biochemistry, Biotechnology and Bioinformatics
Spielmannstr. 7, 38106 Braunschweig, Germany
Phone: +49-531-391-5731, Fax: +49-531-391-5763 /

CORAT Therapeutics GmbH: Dr. Andreas Herrmann


Fully human antibodies from healthy donors that neutralise SARS-CoV-2 (Manuscript in revision):

  • Bertoglio, F., Meier, D., Langreder, N., Steinke, S., Rand, U., Simonelli, L., Heine, P. A., Ballmann, R., Schneider, K.-T., Roth, K. D. R., Ruschig, M., Riese, P., Eschke, K., Kim, Y., Schaeckermann, D., Pedotti, M., Kuhn, P., Zock-Emmenthal, S., Wöhrle, J., Becker, M., Grashoff, M., Wenzel, E. V., Russo, G., Kröger, A., Brunotte, L., Ludwig, S., Fühner, V., Krämer, S. D., Dübel, S., Varani, L., Roth, G., Cicin-Sain, L., Schubert, M. & Hust, M. (2020) SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.  bioRxiv doi: 10.1101/2020.06.05.135921

Review (german language)

  • Dübel, S., Hust, M., Frenzel, A. & Schirrmann, T. (2020) Rekombinante, vollständig menschliche Antikörper zur Behandlung akuter COVID-19. BIOSpektrum (Springer-Verlag, Heidelberg) 4.20, 444-446.  DOI: 10.1007/s12268-020-1404-4